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Parkinson’s disease (PD) and associated 
dopaminergic medications, such as levodopa 
and dopamine agonists, have differential 
effects on cognition. Dopamine medications 
might either enhance or impair cognition in 
PD patients depending on type of cognitive 
task and medication used. In a recent neu-
ropsychological study, Graef and colleagues 
have tested the effects of PD and levodopa 
monotherapy on feedback and reversal learn-
ing. In feedback learning, subjects learn to 
select stimuli, based on either rewarding 
(positive) or punishing (negative) feedback 
to their responses. Thus, reward learning 
involves learning to select responses that 
lead to reward, while punishment learning 
involves learning to avoid responses that 
lead to negative outcome. In reversal learn-
ing tasks, subjects initially learn to associate 
different stimuli with different responses, and 
subsequently learn to associate the same stim-
uli with the opposite responses (i.e., reversal). 
Graef et al. have found that levodopa enhances 
reward learning but impairs reversal learn-
ing in PD patients. This finding is consistent 
with earlier reports that dopamine medica-
tions enhances reward learning (Frank et al., 
2004; Moustafa et al., 2008a; Bodi et al., 2009; 
Palminteri et al., 2009) but impairs reversal 
learning (Swainson et al., 2000; Cools et al., 
2001) in PD patients.
One notable aspect of the current study 
is Graef et al. have tested PD patients on 
levodopa only. This is contrasted from prior 
studies that have recruited PD patients on 
multiple therapies including levodopa and 
dopamine agonists (Cools et al., 2001; Frank 
et al., 2004; Moustafa et al., 2008b; Bodi et al., 
2009), thus confounding dissociable effects of 
levodopa vs. dopamine agonists on cognition. 
Furthermore, the Graef et al. findings are in 
agreement with other studies showing that the 
administration of levodopa enhances feedback 
learning in rats (Pavlis et al., 2006), healthy 
subjects (Knecht et al., 2004; Pessiglione et al., 
2006; Floel et al., 2008; Pleger et al., 2009), 
stroke patients (Scheidtmann et al., 2001; 
Rosser et al., 2008), and PD patients (Beeler 
et al., 2010; de Vries et al., 2010).
Interestingly, Graef et al. have also found 
that the administration of different doses 
of levodopa to PD patients does not affect 
reward learning, that is, levodopa has no dose 
effect on reward learning. This is in line with 
the fact that levodopa is a dopamine pre-
cursor, taken up by dopamine neurons and 
converted into dopamine, and thus largely 
produced in natural conditions. Accordingly, 
an increase of doses of levodopa may not sig-
nificantly alter presynaptic dopamine levels 
in the basal ganglia, and thus may not impact 
cognition, as reported in the Graef study. This 
is, however, contrasted with the effects of dif-
ferent doses of dopamine agonists on cogni-
tion. For example, studies have found that 
in healthy subjects, a low-dose (1.25 mg) of 
the dopamine agonist bromocriptine has no 
effect or impairs working memory (Gibbs and 
D’Esposito, 2005) while a high-dose (2.5 mg) 
of bromocriptine enhances working memory 
(Luciana et al., 1992; Luciana and Collins, 
1997; McDowell, et al., 1998). It is possible 
that a larger dose of dopamine agonists fur-
ther increase postsynaptic dopamine in the 
basal ganglia and prefrontal cortex (Moustafa 
and Gluck, 2011), and thus explain how dif-
ferent doses of dopamine agonists are associ-
ated with dissociable cognitive function.
Another notable finding in the Graef 
et al. study is in addition to reward  learning, 
levodopa also ameliorates depression and 
motor performance (as measured by the 
Beck Depression Inventory and UPDRS 
scales) but has no effect on Mini-Mental State 
Exam (MMSE). This is in line with findings 
that depression and motor performance are 
related to basal ganglia dopamine function 
(Walter et al., 2010), while MMSE scores are 
associated with medial temporal lobe function 
(Ikeda et al., 2008; Ding et al., 2009), which is 
thought to be intact in PD patients.
One unresolved issue in the literature is 
the confounding results regarding the effects 
of dopamine medications on feedback learn-
ing and reversal learning. With regards to 
feedback learning, unlike Graef et al. results, 
other studies have found that the administra-
tion of dopamine medications to PD patients 
impairs or has no effect on feedback learn-
ing (Czernecki et al., 2002; Shohamy et al., 
2006; Jahanshahi et al., 2009). Similarly, stud-
ies have shown that the administration of 
dopamine medications to PD patients either 
enhances or has no effect on reversal learn-
ing (Czernecki et al., 2002; Rutledge et al., 
2009), unlike what Graef et al. have found. 
It is important to note that unlike the Graef 
study, other studies have tested PD patients 
on multiple therapies, including levodopa 
and dopamine agonists, which might explain 
the different results in these studies. Along the 
same lines, Feigin et al. (2003) have found that 
the administration of levodopa slightly (but 
not significantly) impairs sequence learning in 
PD patients. Sequence learning is a feedback 
learning paradigm in which subjects learn 
to make a “sequence” of motor responses, 
based on corrective feedback. Feigin et al. 
have tested PD patients who were on both 
levodopa and dopamine agonists, but were 
only on levodopa during the time of test-
ing. Differences between the Graef et al. and 
Feigin et al. results could be due to long-term 
effects of the intake of dopamine agonists on 
cognition in the Feigin et al. study.
How would dopamine replacement ther-
apies enhance reward learning but impair 
reversal learning? There are two theories that 
explain Graef et al. results. Frank (2005) argue 
that the basal ganglia direct pathway (along 
with dopamine D1 receptors) is required for 
reward learning, while the indirect pathways 
(along with dopamine D2 receptors) is essen-
tial for punishment learning, which involves 
learning to avoid responses that lead to neg-
ative feedback. Frank further argues that 
dopamine  medications increase dopamine 
Moustafa Cognitive effects of levodopa in parkinonism
Frontiers in Human Neuroscience www.frontiersin.org January 2011 | Volume 4 | Article 240 | 2
medication and task demands. Cereb. Cortex 11, 
1136–1143.
Costa, A., Peppe, A., Dell’Agnello, G., Carlesimo, G. A., 
Murri, L., Bonuccelli, U., and Caltagirone, C. (2003). 
Dopaminergic modulation of visual-spatial working 
memory in Parkinson’s disease. Dement. Geriatr. Cogn. 
Disord. 15, 55–66.
Czernecki, V., Pillon, B., Houeto, J. L., Pochon, J. B., 
Levy, R., and Dubois, B. (2002). Motivation, reward, 
and Parkinson’s disease: influence of dopatherapy. 
Neuropsychologia 40, 2257–2267.
de Vries, M. H., Ulte, C., Zwitserlood, P., Szymanski, B., and 
Knecht, S. (2010). Increasing dopamine levels in the 
brain improves feedback-based procedural learning in 
healthy participants: an artificial-grammar-learning 
experiment. Neuropsychologia 48, 3193–3197.
Ding, B., Chen, K. M., Ling, H. W., Sun, F., Li, X., Wan, 
T., Chai, W. M., Zhang, H., Zhan, Y., and Guan, Y. J. 
(2009). Correlation of iron in the hippocampus with 
MMSE in patients with Alzheimer’s disease. J. Magn. 
Reson. Imaging 29, 793–798.
Feigin, A., Ghilardi, M. F., Carbon, M., Edwards, C., 
Fukuda, M., Dhawan, V., Margouleff, C., Ghez, C., 
and Eidelberg, D. (2003). Effects of levodopa on motor 
sequence learning in Parkinson’s disease. Neurology 
60, 1744–1749.
Floel, A., Vomhof, P., Lorenzen, A., Roesser, N., 
Breitenstein, C., and Knecht, S. (2008). Levodopa 
improves skilled hand functions in the elderly. Eur. 
J. Neurosci. 27, 1301–1307.
Frank, M. J. (2005). Dynamic dopamine modulation in 
the basal ganglia: a neurocomputational account of 
cognitive deficits in medicated and nonmedicated 
Parkinsonism. J. Cogn. Neurosci. 17, 51–72.
Frank, M. J., Seeberger, L. C., and O’Reilly, R. C. (2004). 
By carrot or by stick: cognitive reinforcement learning 
in parkinsonism. Science 306, 1940–1943.
Gibbs, S. E., and D’Esposito, M. (2005). A functional MRI 
study of the effects of bromocriptine, a dopamine 
receptor agonist, on component processes of working 
memory. Psychopharmacology (Berl.) 180, 644–653.
Ikeda, E., Shiozaki, K., Takahashi, N., Togo, T., Odawara, 
T., Oka, T., Inoue, T., and Hirayasu, Y. (2008). Total 
Mini-Mental State Examination score and regional 
cerebral blood flow using Z score imaging and auto-
mated ROI analysis software in subjects with memory 
impairment. Ann. Nucl. Med. 22, 539–542.
Jahanshahi, M., Wilkinson, L., Gahir, H., Dharminda, 
A., and Lagnado, D. A. (2009). Medication impairs 
probabilistic classification learning in Parkinson’s 
disease. Neuropsychologia 48, 1096–103.
Knecht, S., Breitenstein, C., Bushuven, S., Wailke, S., 
Kamping, S., Floel, A., Zwitserlood, P., and Ringelstein, 
E. B. (2004). Levodopa: faster and better word learning 
in normal humans. Ann. Neurol. 56, 20–26.
Luciana, M., and Collins, P. (1997). Dopaminergic 
modulation of working memory for spatial but not 
object cues in normal humans. J. Cogn. Neurosci. 9, 
330–347.
Luciana, M., Depue, R. A., Arbisi, P., and Leon, A. (1992). 
Facilitation of working memory in humans by a D2 
dopamine receptor agonist. J. Cogn. Neurosci. 4, 
58–68.
McDowell, S., Whyte, J., and D’Esposito, M. (1998). 
Differential effect of a dopaminergic agonist on pre-
frontal function in traumatic brain injury patients. 
Brain 121(Pt 6), 1155–1164.
Moustafa, A. A., Cohen, M. X., Sherman, S. J., and Frank, 
M. J. (2008a). A role for dopamine in  temporal  decision 
levels in the basal ganglia and enhance reward 
learning via D1 receptors, but impair punish-
ment learning via D2 receptors. According 
to Frank, following reversal of reward con-
tingencies in the reversal learning task, sub-
jects are more likely to receive more negative 
feedback, and thus an inability to learn from 
negative feedback will lead to reversal learn-
ing impairment in medicated PD patients. 
An alternative theory is proposed by Cools 
et al. (2001), which argue that while the ven-
tral striatum is intact in PD patients, dorsal 
striatum is dysfunctional. Cools et al. further 
argue that reward learning is mediated by the 
dorsal striatum while punishment learning 
by the ventral striatum. According to Cools, 
dopamine medications ameliorate the func-
tion of the dorsal striatum, but overdose the 
ventral striatum and orbitofrontal cortex 
loop, and thus enhance reward learning 
but impair reversal learning. Moustafa and 
Gluck (under review) have recently built a 
computational model showing how overdos-
ing cortical areas impair reversal learning in 
medicated PD patients, as reported by Graef 
et al.
Overall, Graef and colleagues have 
shown that the administration of levodopa 
monotherapy has both enhancing and del-
eterious effects on cognition in PD patients. 
Future research should investigate the dis-
sociable effects of levodopa vs. dopamine 
agonists on cognition in PD patients. To 
my knowledge, studying differential effects 
of dopamine replacement therapies in PD 
patients has been only conducted using 
working memory tasks (Brusa et al., 2003; 
Costa et al., 2003), but not with reward and 
reversal learning paradigms.
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